164 related articles for article (PubMed ID: 35210509)
1. Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma.
Tanaka T; Sakai R; Choi I; Tsukada J; Sasaki H; Naito Y; Kiyomi F; Takamatsu Y; Tamura K
Sci Rep; 2022 Feb; 12(1):3124. PubMed ID: 35210509
[TBL] [Abstract][Full Text] [Related]
2. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
Spina M; Balzarotti M; Uziel L; Ferreri AJ; Fratino L; Magagnoli M; Talamini R; Giacalone A; Ravaioli E; Chimienti E; Berretta M; Lleshi A; Santoro A; Tirelli U
Oncologist; 2012; 17(6):838-46. PubMed ID: 22610154
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.
Ong DM; Ashby M; Grigg A; Gard G; Ng ZY; Huang HE; Chong YS; Cheah CY; Devitt B; Chong G; Loh Z; Mo A; Hawkes EA
Br J Haematol; 2019 Oct; 187(1):73-81. PubMed ID: 31206608
[TBL] [Abstract][Full Text] [Related]
5. Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B-Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment.
Liu H; Zhang CL; Feng R; Li JT; Tian Y; Wang T
Oncologist; 2018 Jun; 23(6):722-729. PubMed ID: 29317552
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Treatment Outcomes and Geriatric Assessment in Elderly Malignant Lymphoma Patients.
Naito Y; Sasaki H; Takamatsu Y; Kiyomi F; Tamura K
J Clin Exp Hematop; 2016; 56(1):43-9. PubMed ID: 27334857
[TBL] [Abstract][Full Text] [Related]
7. Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.
Yhim HY; Park Y; Kim JA; Shin HJ; Do YR; Moon JH; Kim MK; Lee WS; Kim DS; Lee MW; Choi YS; Jeong SH; Kim KH; Kim J; Lee CH; Song GY; Yang DH; Kwak JY
Korean J Intern Med; 2024 May; 39(3):501-512. PubMed ID: 38287501
[TBL] [Abstract][Full Text] [Related]
8. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
[TBL] [Abstract][Full Text] [Related]
9. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.
Yoshida M; Nakao T; Horiuchi M; Ueda H; Hagihara K; Kanashima H; Inoue T; Sakamoto E; Hirai M; Koh H; Nakane T; Hino M; Yamane T
Eur J Haematol; 2016 Apr; 96(4):409-16. PubMed ID: 26084899
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study.
Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
Eur Geriatr Med; 2022 Feb; 13(1):195-201. PubMed ID: 34254266
[TBL] [Abstract][Full Text] [Related]
11. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.
Olivieri A; Gini G; Bocci C; Montanari M; Trappolini S; Olivieri J; Brunori M; Catarini M; Guiducci B; Isidori A; Alesiani F; Giuliodori L; Marcellini M; Visani G; Poloni A; Leoni P
Oncologist; 2012; 17(5):663-72. PubMed ID: 22531362
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G
Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776
[TBL] [Abstract][Full Text] [Related]
13. Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma.
Oiwa K; Fujita K; Lee S; Morishita T; Tsukasaki H; Negoro E; Ueda T; Yamauchi T
Oncologist; 2021 Mar; 26(3):215-223. PubMed ID: 33320984
[TBL] [Abstract][Full Text] [Related]
14. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).
Tucci A; Martelli M; Rigacci L; Riccomagno P; Cabras MG; Salvi F; Stelitano C; Fabbri A; Storti S; Fogazzi S; Mancuso S; Brugiatelli M; Fama A; Paesano P; Puccini B; Bottelli C; Dalceggio D; Bertagna F; Rossi G; Spina M;
Leuk Lymphoma; 2015 Apr; 56(4):921-6. PubMed ID: 25110825
[TBL] [Abstract][Full Text] [Related]
16. Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma.
Sakurai M; Karigane D; Kasahara H; Tanigawa T; Ishida A; Murakami H; Kikuchi M; Kohashi S
Ann Hematol; 2019 Mar; 98(3):669-678. PubMed ID: 30443764
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
18. [Comprehensive geriatric assessment can predict the clinical outcomes of elderly patients with diffuse large B cell lymphoma in China].
Zhang CL; Feng R; Li JT; Tian Y; Wang T; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):271-276. PubMed ID: 29779319
[No Abstract] [Full Text] [Related]
19. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]